Spiramycine

Phase 3Small molecule

AAssistance Publique - Hôpitaux de Paris

Spiramycine is one of 5 small molecule programs targeting Congenital Toxoplasmosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Congenital ToxoplasmosisActive, not recruiting

Congenital ToxoplasmosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Congenital Toxoplasmosis

#DrugCompanyPhaseTrials

Daraprim

FFondazione Matilde Tettamanti Menotti De Marchi Onlus

Approved

1 2

Wellcovorin

EEastern Cooperative Oncology Group

Approved

1 3

Sulfadiazine Sodium

Eli Lilly

Approved

1 4

Spiramycin

RRhone-Poulenc Rorer

Approved

1 5

Spiramycine

AAssistance Publique - Hôpitaux de Paris

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Congenital Toxoplasmosis1 trial

Prevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT01189448·149 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Spiramycine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Spiramycine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Spiramycine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

Spiramycine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Congenital Toxoplasmosis1 trial

References

Drug Info

Quick Facts

Related News